CYP2C19 pharmacogenetics versus standard of care dosing for selecting antiplatelet therapy in patients with coronary artery disease: A meta ‐analysis of randomized clinical trials

ConclusionIn patients undergoing stent implantation, MACE with genotype ‐guided therapy was not significantly reduced; however, there was a signal towards reduction of MACE in ACS patients, as well as a lower rate of MI, though this will require further confirmation in adequately powered trials.

Source: Catheterization and Cardiovascular Interventions - November 7, 2018 Category: Cardiovascular & Thoracic Surgery Authors: Babikir Kheiri, Mohammed Osman, Ahmed Abdalla, Tarek Haykal, Pranay V. Pandrangi, Adam Chahine, Sahar Ahmed, Khansa Osman, Ghassan Bachuwa, Mustafa Hassan, Deepak L. Bhatt Tags: CORONARY ARTERY DISEASE Source Type: research